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gene expression in response to manipulating the actin cytoskeleton in
chondrocytes.
Methods: Chondrocytes isolated from embryonic mice growth plates
were plated in high density monolayer cultures and treated for 24 hours
with vehicle, 10mM Y27632 (inhibits Rho/ROCK signaling), 1mM cytocha-
lasin D (inhibits actin polymerization) or 50 nM jasplakinolide (promotes
actin polymerization). RNA was isolated, and then hybridized to Affymetrix
MOE4.0 chips. Bioinformatic analysis (MAS5.0) was performed and probe
sets demonstrating a signiﬁcant, at least 1.5-fold change and reliable
signal were considered for further analysis. These data were compared
to our previous microarray analyses of chondrocyte differentiation in vitro
and in vivo (growth plate zones of microdissected tibia, time course of mi-
cromass cultures differentiating from mesenchymal cells to hypertrophy)
we have previously analyzed.
Results: Inhibition of actin polymerization by cytochalasin D resulted in
the most compelling data in comparison to other actin manipulations.
We observed that treating growth plates with cytochalasin D resulted in
very large bones consisting entirely of cells with hypertrophic morphology.
Analysis of the gene set revealed that most genes that were upregulated
were similarly regulated in other models of chondrocyte differentiation
to hypertrophy, suggesting that cytochalasin D stimulates chondrocyte
hypertrophy, a novel ﬁnding. We continued our studies by comparing
gene sets with other models of chondrocyte hypertrophy and identiﬁed
the nuclear receptor, Rora as a common gene upregulated in all 3 models
studied. We found that Rora is most highly expressed in the hypertrophic
portion of the growth plate and is expressed throughout growth plates of
cytochalasin D treated bones. Additionally, multiple targets of Rora are
also increased in chondrocytes treated with cytochalasin D, such as fatty
acid binding protein 4, lipoprotein lipase and CD36 (a receptor previously
implicated in osteoarthritis). We also show that stimulation of Rora
by its ligand cholesterol results in a phenotype similar to chondrocyte
hypertrophy. These data suggest that cholesterol signaling through Rora
contributes to chondrocyte hypertrophy.
Interestingly, because it has been shown in other cell types that Rora
expression is regulated by Hif1a, we assessed and conﬁrmed increased
levels of Hif1a in the hypertrophic region of the growth plate and through-
out the growth plates of bones treated with cytochalasin D. Similarly, Rora
and Hif1a expression was upregulated in chondrocytes with cartilage-
speciﬁc deletion of the Rac1 gene.
Conclusions: Identiﬁcation of regulators of chondrocyte hypertrophy
will be essential in preventing pathological differentiation of articular
chondrocytes in osteoarthritis. Our data implicate the nuclear receptor
Rora and its activator cholesterol in stimulating chondrocyte hypertrophy.
These data have far reaching implications for preventing and possibly
minimalizing the severity of osteoarthritis.
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Purpose: Osteoarthritis (OA) involves the degeneration of articular car-
tilage by catabolic factors. Previously, we determined that transform-
ing growth factor alpha (TGF alpha) gene expression was upregulated
in articular chondrocytes in an experimental OA model. Furthermore
we demonstrated that TGF alpha suppressed chondrocyte phenotype
and speciﬁcally induced expression of catabolic factors including matrix
metalloproteinase-13. Thus we identiﬁed TGF alpha as a candidate
causal factor in OA. Our subsequent goal was to determine downstream
targets of TGF alpha. Interestingly, microarray data from our OA model
indicate that endothelin receptor A (ETA) expression is also upregulated
in the disease state. Since ETA has already been implicated in OA and
other age-related diseases we decided to investigate whether there was
a connection between TGF alpha and ETA signaling.
The purpose of the current study was to (1) examine the upregulation
of ETA in our experimental OA model, (2) determine the effects of TGF
alpha on ETA expression, (3) evaluate whether the catabolic effects of
TGF alpha can be inhibited by blocking ETA.
Methods: RNA and histological cartilage sections from our rodent OA
model were evaluated for ETA gene and protein expression by real-
time PCR and immunohistochemistry respectively. Next primary articular
chondrocytes were isolated from newborn Sprague Dawley rats, grown
in monolayer cultures, and treated with TGF alpha (10 ng/ml) for up to
3 days. RNA was isolated from cultures and the expression of genes
implicated in OA was assessed by real-time PCR. We then isolated
articular cartilage organ culture explants and treated them with TGF
alpha for up to 7 days. Explants were sectioned and immunostained for
both ETA and inducible nitric oxide synthase (iNOS). Next we used an
endothelin receptor inhibitor in an attempt to block some of TGF alpha’s
catabolic effects. Chondrocyte cultures were treated with either vehicle,
TGF alpha, inhibitor (10mM), or a combination of both for 48 hours.
RNA was isolated and real-time PCR was performed for genes including
Mmp13, Col2a1, and Agc1.
Results: Data revealed a signiﬁcant increase in ETA gene expression
in OA animals compared to controls. There also appeared to be deeper
ETA staining in cartilage from OA animals compared to controls. In cell
cultures, Cxcr4, Tgfa and Il1b gene expression did not change after
treatment, while the expression of Ednra (ETA gene) and Tnfa increased
in response to TGF alpha. Immunohistochemistry showed that explants
treated with TGF alpha expressed more ETA than did controls. The
endothelin receptor inhibitor did not appear to block TGF alpha’s induction
of Mmp13 or inhibition of Col2a1 and Agc1 expression by TGF alpha.
Organ culture explants demonstrated an increase in iNOS expression in
TGF alpha-treated tissues compared to controls. Our current cell cultures
studies suggest that TGF alpha treatment results in increased production
of nitric oxide that can be partially blocked by inhibition of endothelin
signaling.
Conclusions: ETA expression was upregulated in our animal model of
OA as well as in TGF alpha-treated chondrocyte cultures and articular
cartilage organ cultures. Preliminary data suggest that blocking ETA may
inhibit a TGF alpha-induced increase in nitric oxide production. Thus, in
addition to TGF alpha, ETA may be another therapeutic target for OA
treatment. While blocking ETA did not appear to alter TGF alpha’s effects
on Mmp13, Col2a1 and Agc1 expression, future experiments will focus
on studying protein levels of these genes.
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Purpose: Although EPAS1 plays essential roles in hypoxia and many
pathogenic conditions, the function of EPAS1 in articular chondrocytes
is unclear. In this study, we characterized a role of EPAS1 in cartilage
destruction.
Methods: EPAS1 expression and function in primary culture rabbit ar-
ticular chondrocytes were studied by RT-PCR and qRT-PCR analysis.
A role of EPAS1 in MMP expression was determined by reporter gene
assay. In vivo role of EPAS1 was examined by using collagenase- induced
osteoarthritis model using EPAS1 deﬁcient (EPAS1+/−) mouse.
Results: In primary culture articular chondrocytes, EPAS1 expression
was signiﬁcantly increased during dedifferentiation caused by interleukin-
1beta (Il-1b), epidermal growth factor, retinoic acid, or serial subculture
as monolayer. Dedifferentiation of chondrocyte accompanies induction of
several matrix metalloproteinases (MMPs) expression such as MMP-1, -3,
-9, -12, and -13, but not MMP-2, -14, and -15. Overexpression of EPAS1
by adenovires-EPAS1 induced MMP-1, -3, -9, -12, and -13 expressions,
whereas knockdown of EPAS1 by siRNA blocked Il-1b-induced expres-
sion of these MMPs. Regulatory mechanism of MMP expression was
further examined by reporter gene containing individual MMP promoter.
Reporter gene activity of MMP-1, -3, -9, -12, and -13 increased by EPAS1
transfection, and the increased activity was blocked by point mutation of
EPAS1 binding site (−CGTG−) or dominant negative EPAS1. In vivo role
of EPAS1 was examined by using EPAS1 deﬁcient (EPAS1+/−) mice, and
found that EPAS1 knockdown signiﬁcantly reduced collagenase-induced
osteoarthritis.
Conclusions: We demonstrated that EPAS1 in chondrocytes regulates
expression of MMP-1, -3, -9, -12, and -13, and EPAS1 knockdown
reduces collagenase-induced osteoarthritis in mice. Our results suggest
that EPAS1 may play a role in cartilage destruction by modulating MMP
expression.
